Text Size
   
YouCMSAndBlog Module Generator Wizard Plugin

AXXE

Members,

How does a potential 457% Return On Investment sound to you?

Pretty impressive don't you agree...

Well those are exactly the type of returns analysts are predicting for our new pick AXXE ( Axxess Pharma Inc.) for traders who pick up shares of what we feel is a grossly undervalued price of just $0.251!

Based on their most recent research report, analysts at Murphy Analytics believe AXXE has the opportunity to justify a stock price approaching $0.90 based on $18 million in revenue and a stock price of nearly $1.40 over the coming quarters if AXXE is able to demonstrate an ability to deliver revenue as projected and growth in revenue that seems possible based on the Company’s expanded distribution network.

AXXE is a specialty health care product company that is dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas.

Today, AXXE announce that through its wholly owned subsidiary AllStar Health Brands Inc., that they have secured $2,000,000 USD in financing. Funds will be used to fulfill current purchase orders and increase marketing and inventory of products. Management will also quickly add new high-demand products that have been requested by buyers to round out the TapouT Muscle Growth and Recovery line.

Daniel Bagi, M.D., President of Axxess Pharma stated: "This is another major milestone for Axxess Pharma. We continue expanding revenue while having funds to fulfill all orders, increase marketing and introduce high-demand products to market. Our TapouT-branded premium products are offered to individuals focused on improving Quality of Life at every age."

The market responded positively to this news, and AXXE closed the day up (+5.91%) on heavy trade volume!

We believe today's surge in price is just start of even bigger things to come for AXXE...

AXXE appears to be well on its way to surpassing the 1 dollar mark, and with with more news rumored to be hitting the wire as early as tomorrow, traders could be treated to substantial gains tomorrow, and the days and weeks to follow!

The time to take action is now, and we are urging all members to immediately start their research on AXXE, and be ready to take action early tomorrow at 9:30am EST!

Please review AXXE'S Chart, latest news, and full profile below:

Company: Axxess Pharma Inc.
Current PPS: $0.251

Outstanding Shares: 45.4M

Website: www.axxesspharmainc.com tapout.com

About The Company:

Axxess Pharma Inc. (PINKSHEETS: AXXE) is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.

AXXE’s 23 wholly owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, high cholesterol, blood pressure, acute pain, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more and generate annual sales in excess of $3 million. Likewise, the company will re-launch its highly demanded product that for iron deficiency which has had previous sales in excess of $2 million and can very well exceed futures sales of $5 million - $7 million. Additionally, the company holds a Licensing Agreement with a Canadian manufacturer in which the company now has full rights to a suite of cancer drugs for the Mexican market.

Furthermore, through the company’s other subsidiary, AllStar Health Brands Inc., the company has acquired worldwide exclusive rights with the globally known Mixed Martial Arts Brand, TapouT, to market and sell a full line of pain relief and muscle recovery products, as well as develop and market a vitamin line under the TapouT brand. The product line includes 5-FDA and Health Canada Approved Products such “Extreme Muscle” which combines top of the line natural ingredients to naturally boost testosterone levels, build muscle, burn fat, and enhance the libido; and “Muscle Explosion”, an all-natural muscle strength and growth formula for pre-and post-workout regimens.

Overwhelming response to the launch of these products have occurred with a Sellout of an Initial Order to a leading Canadian distributor, celebrity endorsements with Champion Bodybuilder Michael Spencer,Two-Time Canadian Heavyweight Boxing Champion Ray Olubowale, Cross-Fit Athlete Catia James, and launching in over 4,500 websites.

In a 3/17/14 press release addressing the Company’s marketing campaign, AXXE announced an expectation that revenue may reach $1.5 million monthly, putting the company at an $18 million run rate 2 years ahead of the schedule outlined in the Company’s business plan. A review of AXXE press releases over the preceding quarters sheds light on the Company’s optimism as AXXE has made a significant number of improvements and expansions of its distribution channels, product lineup, marketing efforts, and corporate operations. The Company’s 5/1/14 announcement that TapouT will be available in over 160 U.S. military stores reflects both the substantial progress AXXE has made as well as the opportunity before the company. Commenting on the agreement, AXXE CEO Dr. Daniel Bagi stated:

"This purchase order represents many months of working together with Acosta, one of the largest US distributors. We are extremely pleased with this initial and substantial order. The Army and Air Force (AAFES) have 130 bases in the US and world-wide. However, world-wide there are 2,817 facilities in 30 countries, all fifty states and five US territories. These world-wide facilities include embassies and small bases where we have troops stationed -- like in Sarajevo. World-wide retail sales from AAFES facilities, last year reached $9.2 Billion."
An $18 million revenue run rate has the potential to deliver $2.3 million in earnings for AXXE. Additionally, given the vast expansion of the Company’s distribution network, particularly the military channel, it seems reasonable to conclude that there is a significant revenue growth opportunity before the Company. Murphy Analytics expects AXXE has the opportunity to justify a stock price approaching $0.90 based on $18 million in revenue and a stock price of nearly $1.40 over the coming quarters if AXXE is able to demonstrate an ability to deliver revenue as projected and growth in revenue that seems possible based on the Company’s expanded distribution network.

Market

According to Global Industry Analysts, Inc. (GIA), the pain-management industry will earn US $60 billion by the year 2015. GIA cites the following factors that are driving this growth industry.

  • An aging population worldwide
  • More surgical procedures being performed
  • Changing lifestyles (for the worse)
  • An increasing incidence of cancer

The U.S. market for pain-management therapeutics is estimated to generate more than 40B USD and is predicted to grow to 60B USD by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer pain, arthritis pain, migraine pain, neuropathic pain, and back pain.

This medical segment consists of products such as opioids, nonsteroidal anti-inflammatory drugs, acetaminophen, local anesthetics, tricyclic antidepressants, anticonvulsants, patient-controlled dosing, implants, and electrical stimulation.

Many pain medications, while effective, cause unwanted side effects. Opioids, the largest pain-therapy class, are widely known to cause a number of side effects such as nausea, vomiting, constipation, and somnolence. They can also cause severe respiratory depression. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to cause gastrointestinal upset, kidney and liver damage, and they can increase cardiovascular risks.

A higher demand for more efficient drugs, delivery systems, and medical devices for pain treatment is driving the pain-management market. The need to address acute and chronic pain will rise alongside an increasingly aging population. Other factors affecting the future of the pain-management segment include a growing number of surgical procedures being performed, changing lifestyles, and increasing incidences of cancer.

TapouT has powered the Mixed Martial Arts industry since its inception in 1997 and has rapidly grown into other sports and categories including offering merchandise for men, women, and children.

TapouT endorses high profile professional athletes from MMA, NBA, MLB, and NASCAR.

The TapOut brand can be found at numerous sporting goods stores, specialty retailers, and online.

Aside from the U.S, the TapouT brand has a large presence in other large countries including Brazil, China, and India.

The TapouT brand generated $200 million in revenues in 2012; over 16 times its $12 million revenue in 2006.

Recent News
New Distribution Agreement has been announced for expansion into Australia and Asia.
AXXE has expanded its global sales with an initial order from an Australian Distributor.
The company has announced its TapouT Muscle Recovery Line is Gaining Strong Momentum in the U.S after completely selling out on Amazon.com earlier in the year.
AXXE Received Strong Interest from several international distributors, specifically those in Europe and Latin America, at a recent UFC Fan Expo Event in Las Vegas.
AXXE will Meet 50,000 New Distributors at the 2014 Olympia Fitness & Performance Expo in Las Vegas this September.
Audited financials and S-1 registration statements have been filed with the SEC for the company to Uplist to OTC:BB Stock Exchange.
As you can see, this summer has been jam packed with market friendly news regarding AXXE and their aggressive growth strategy.
These updates could serve as strong catalysts for a long and steady uptrend back to the 1 dollar mark!
We believe this is the last time you will be seeing AXXE trading under $0.30 for a long time, and we are urging all members to add AXXE to their radar immediately and be ready early tomorrow at 9:30am EST!
Let's get ready for an exciting day of trading...

Remember the first step to becoming a successful penny stock trader is opening up a brokerage account if you haven't done so already you can start by clicking here.

***Always Trade Smart & Take Profits When You Can***

Sincerely,

The PennyStockLocks Team

P.S.

Share the wealth and forward this email to all your fellow traders who have yet to join the fastest growing network of serious traders on the web.

Axxess Pharma Inc. Secures $2 Million USD in Financing to Fulfill Increased Rate of Purchase Orders

8:02a ET July 30, 2014 (Market Wire) Print
Axxess Pharma Inc. (PINKSHEETS: AXXE) is pleased to announce through its wholly owned subsidiary AllStar Health Brands Inc., that they have secured $2,000,000 USD in financing. Funds will be used to fulfill current purchase orders and increase marketing and inventory of products. Management will also quickly add new high-demand products that have been requested by buyers to round out the TapouT Muscle Growth and Recovery line.

In a joint statement by the Managing Members of Beaufort Capital Partners LLC, Leib Schaeffer and Robert Marino announced, "We are honored to be one of the leading investors in Axxess Pharma, Inc. which continues to push the envelope in medical and nutritional products. These products such as their TapouT line, advance the health, comfort and care of those advancing a healthy lifestyle as well as those afflicted by illness and disease. We can think of no greater corporate calling than to partner with exciting companies on the forefront of nutritional health and alleviating pain and discomfort while affording the users with hope and relief."

Daniel Bagi, M.D., President of Axxess Pharma stated: "This is another major milestone for Axxess Pharma. We continue expanding revenue while having funds to fulfill all orders, increase marketing and introduce high-demand products to market. Our TapouT-branded premium products are offered to individuals focused on improving Quality of Life at every age."

About Axxess Pharma Inc.:

Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, -- to optimal health management through improved nutritional supplements.

For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.

About TapouT:

TapouT is a lifestyle brand that has been at the forefront of Mixed Martial Arts since its inception in 1997. The label is rapidly growing into other sports and categories, offering merchandise for men, women and kids. TapouT has endorsed high-profile professional athletes who compete in sports such as basketball, football, baseball, stock car racing, and most famously, MMA. TapouT is sold in sporting goods stores, specialty retailers and online. For updates and more information, please visit TapouT.com.

https://www.facebook.com/TapouT

https://twitter.com/TapouT

http://www.youtube.com/tapout

-----------------------------------------------------

Follow Us On:

Disclaimer:

PennyStockLocks LLC has been compensated  $10,000 on 7-31-2014 for the awareness of AXXE from a third party Ramos & Ramos.

FREE Stock Alerts

 

Partner Sites

Follow Us On

As Seen On...

IHUB

MarketWatch

Yahoo Finance

Google Finance

MSN

Penny Stock Picks